Clinical and Translational Core (Core C)

临床和转化核心（核心 C）

• 批准号: 10203940
• 负责人: Tamara Isakova
• 金额: $ 23.22万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10203940
• 关键词: Affect; American; Award; Bioethics; Bioethics Consultants; Bioinformatics; Biological Markers; Biological Specimen Banks; Cardiovascular Diseases; Cessation of life; Chronic Kidney Failure; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Cohort Studies; Collaborations; Communities; Computerized Medical Record; Data; Data Analyses; Data Collection; Development; Discipline; End stage renal failure; Ensure; Environment; Epidemiology; Ethicists; Ethics; Financial Hardship; Funding; Goals; Health; Health Care Costs; Healthcare Systems; Human Subject Research; Humanities; Impairment; Individual; Institution; Investments; Kidney; Kidney Diseases; Lead; Location; Longevity; Medical; Methodology; Methods; Modality; Nephrology; Observational Study; Outcome; Participant; Pathogenesis; Patient Outcomes Assessments; Patient Rights; Patients; Phenotype; Physiological; Pilot Projects; Positioning Attribute; Pre-Clinical Model; Prevention; Process; Protocols documentation; Provider; Quality Control; Quality of life; Research; Research Design; Research Infrastructure; Research Personnel; Research Support; Resources; Retrieval; Scientific Inquiry; Security; Services; Speed; System; Talents; Therapeutic; Translating; Translational Research; Translations; Universities; Work; adverse outcome; base; biobank; biomedical informatics; clinical translation; clinically relevant; community based participatory research; community based research; comorbidity; data management; data repository; design; ethnic diversity; experience; first-in-human; high risk; improved; inclusion criteria; model development; multidisciplinary; novel; novel therapeutics; patient population; pre-clinical; premature; racial diversity; research and development; research study; sound; statistics; study population; therapeutic development

PROJECT SUMMARY TO CLINICAL AND TRANSLATION CORE Kidney diseases predispose affected individuals to high rates of end stage renal disease (ESRD), cardiovascular disease (CVD) and premature death. With nearly 30 million Americans estimated to have chronic kidney disease, the healthcare costs are tremendous. Identification of novel mechanisms for the pathogenesis of kidney diseases and related complications is urgently needed to improve adverse clinical outcomes and to reduce the financial burden on the US healthcare system. The George M. O'Brien Kidney Research Core Center at Northwestern University (NU-GoKIDNEY) will promote and support research into the discovery of novel therapeutics that will transform the prevention and treatment of kidney diseases and eventually lead to cures. The Center will join basic and clinical investigators to conduct translational research focused on the discovery of novel therapeutic modalities for patients with kidney diseases. Research catalyzed by the Preclinical Models Core and the Therapeutics Development Core will lead to discoveries of novel therapies, which will be translated into patients through the activities of the Clinical and Translational Core. The Core Leaders will work together to synergistically advance the Center’s chief goal of finding new treatments that will improve the lives of patients with kidney diseases. The Clinical and Translational Core will provide a centralized environment, essential resources and multi- disciplinary expertise to safely and ethically translate and target the discoveries identified by the Preclinical Model and Therapeutics Development Cores into the right patient population. We will efficiently connect investigators with: (1) the most appropriate components of the existing clinical research infrastructure; (2) relevant analytic experts; (3) well-matched talent in methods not commonly used in nephrology research, (4) unique data and biosample repositories; and (5) community-based research study participants and leaders in bioethics and medical humanities. Our goals are: (1) to enhance the integration of institutional strengths in clinical research; (2) to encourage cross-disciplinary collaboration within and between the Cores; (3) to introduce new disciplines into the field of kidney diseases research; (4) to improve the ability of investigators to phenotype participants through access to data and biosample repositories; and (5) to enrich the experience of study participants by enlisting involvement of bioethicists, study participants and community providers in the development of research protocols. By leveraging our strong institutional environment, existing resources and multidisciplinary expertise, the Clinical and Translational Core will accelerate the translation of preclinical discoveries into meaningful health improvements for patients with kidney diseases.

临床和翻译核心的项目总结 肾脏疾病使受影响的个体易患终末期肾脏疾病（ESRD）， 心血管疾病（CVD）和过早死亡。估计有近3000万美国人 慢性肾病的医疗费用是巨大的。确定新的机制， 肾脏疾病及其相关并发症的发病机制，迫切需要改善不良的临床 以减轻美国医疗保健系统的财政负担。该乔治M。奥布莱恩肾 西北大学研究核心中心（NU-GoKIDNEY）将促进和支持研究 发现新的治疗方法，将改变肾脏疾病的预防和治疗， 疾病，并最终治愈。该中心将联合基础和临床研究人员， 转化研究的重点是发现新的治疗方式的患者 肾脏疾病由临床前模型核心和治疗药物开发催化的研究 核心将导致新疗法的发现，这些新疗法将通过以下活动转化为患者 临床和翻译核心。核心领导人将共同努力，协同推进 该中心的主要目标是寻找新的治疗方法，改善肾病患者的生活。的 临床和翻译核心将提供一个集中的环境，必要的资源和多 学科专业知识，以安全和道德地转化和靶向临床前研究所确定的发现 模型和治疗药物开发核心进入正确的患者人群。我们将有效地连接 研究者：（1）现有临床研究基础设施的最适当组成部分;（2） 相关分析专家;（3）在肾脏病学研究中不常用的方法方面具有匹配的人才，（4） 独特的数据和生物样本储存库;（5）社区研究参与者和领导者， 生物伦理学和医学人文学。我们的目标是：（1）加强机构优势的整合， 临床研究;（2）鼓励核心内部和之间的跨学科合作;（3） 在肾脏病研究领域引入新的学科;（4）提高研究者的能力， 表型参与者通过访问数据和生物样品储存库;（5）丰富的经验， 研究参与者通过招募生物伦理学家，研究参与者和社区提供者参与， 制定研究方案。通过利用我们强大的体制环境、现有资源和 多学科专业知识，临床和翻译核心将加速临床前翻译 这些发现对肾脏疾病患者的健康有意义的改善。